SynthaverseWAR:SVE -1.67%55 EBITDA Margin % is 20.00% as of Mar. 2026, which is 20% above its 10-year median of 16.67. GuruFocus rates WAR:SVE with a GF Score™ of 55/100 and a GF Value™ of zł3.04 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 944 Biotechnology companies, Synthaverse ranks better than 57.42% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Synthaverse's EBITDA for the
three
months ended in Mar. 2026 was zł2.72 Mil. Synthaverse's Revenue for the
three
months ended in Mar. 2026 was zł13.61 Mil. Therefore, Synthaverse's EBITDA margin for the quarter that ended in Mar. 2026 was 20.00%.
Synthaverse (WAR:SVE) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Synthaverse EBITDA Margin % Related Terms
Synthaverse EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Synthaverse's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SVE vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Synthaverse's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synthaverse EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Synthaverse's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Synthaverse's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synthaverse (WAR:SVE) has a EBITDA Margin % of 20.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Synthaverse and its competitors. This is 20% above median its historical median of 16.67. According to the industry distribution chart, Synthaverse ranks #402 out of 944 companies in the Biotechnology industry, placing it in the top 42.6%.
Is Synthaverse's EBITDA Margin % too high?
Synthaverse's current EBITDA Margin % of 20.00% is 20% above median its 10-year median of 16.67. Based on the distribution chart, Synthaverse ranks #402 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Synthaverse has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Synthaverse's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Synthaverse ranks #402 out of 944 companies for EBITDA Margin %. This puts Synthaverse in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Synthaverse and its competitors. Synthaverse's current EBITDA Margin % is 20.00%, which is 20% above median its own 10-year median of 16.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synthaverse stock overvalued right now?
Based on GuruFocus' analysis, Synthaverse (WAR:SVE) is currently considered Modestly Undervalued. The stock's GF Value™ is zł3.04, compared to a current price of zł2.66 — trading 12.7% below its estimated fair value. The current EBITDA Margin % is 20.00%, which is 20% above median its 10-year median of 16.67. Synthaverse's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Synthaverse (WAR:SVE), the current EBITDA Margin % is 20.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synthaverse (WAR:SVE) Overvalued in 2026?
Based on GuruFocus' analysis, Synthaverse stock appears to be undervalued.
The current stock price of zł2.66 is trading 12.7% below its estimated GF Value™ of zł3.04.
GuruFocus considers Synthaverse to be Modestly Undervalued.
Key valuation signals for WAR:SVE:
EBITDA Margin %: 20.00% (20% above median its 10-year median of 16.67)
GF Value™: zł3.04 vs. price of zł2.66 (12.7% below fair value)
No single metric tells the full story. See the WAR:SVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synthaverse SA is a global pharmaceutical company. Its goal is to provide the best, innovative and unique solutions for medicine. Its work is based on scientific and health knowledge. Along with its expert approach, it allows the company to create reliable and unique products. It manufactures one of the few drugs used internationally in the oncological immunotherapy of bladder cancer.
55GF Score
Get the complete analysis for WAR:SVE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SVE has been successfully added to your 
